American Century Companies’s 4D Molecular Therapeutics FDMT Stock Holding History

American Century Companies's FDMT Position: Q2 2026 in Review

American Century Companies increased its 4D Molecular Therapeutics (FDMT) stake by 12% in Q2 2026, buying an estimated $122K and bringing the position to 114,000 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2290.

American Century Companies first reported a position in FDMT in Q2 2024 and has held it in 9 quarters since. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

• American Century Companies held 114,000 shares of 4D Molecular Therapeutics worth $1.52M as of Q2 2026.
• American Century Companies bought 12,489 4D Molecular Therapeutics shares in Q2 2026, an estimated $122K.
• 4D Molecular Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2290 holding.
• American Century Companies first reported a position in 4D Molecular Therapeutics in Q2 2024 and has held it in 9 quarters since.
• 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.